Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it creates a small crevice in the mutant protein that is not present in the wild type conformation. This druggable cavity has led to the development of small molecules such as rezatapopt that are designed to restore p53 and reactivate its normal tumor suppressor function. Rezatapopt has shown promising efficacy in early studies, but as with most targeted therapies, patients can eventually develop resistance to treatment.

When childhood cancer treatment ends, the emotional impact often does not. A new study published in the Nature journal Pediatric Research finds that symptoms of post-traumatic stress, anxiety, and depression remain common among childhood cancer survivors and their parents more than a year after treatment has been completed, highlighting the long-term psychological consequences of pediatric cancer.

A research team at the University of Würzburg has, for the first time, uncovered how E. coli bacteria sneak into the prostate. The discovery reveals a hidden infection pathway and opens the door to potential new treatments for bacterial prostatitis.